<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785743</url>
  </required_header>
  <id_info>
    <org_study_id>TJDBPS07</org_study_id>
    <nct_id>NCT03785743</nct_id>
  </id_info>
  <brief_title>Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma</brief_title>
  <official_title>Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy for Pancreatic Carcinoma(TJDBPS07) a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AfÔ¨Åliated Hospital of North Sichuan Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with
      poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC. Minimally
      invasive surgery has been progressively developed, first with the advent of
      hybrid-laparoscopy and recently with the total laparoscopy surgeries, but a number of issues
      are currently being debated, including the superiority between total laparoscopic
      pancreaticoduodenectomy (TLPD)and the open pancreaticoduodenectomy (OPD). Studies comparing
      these two surgery techniques are merging and randomized controlled trials (RCT) are lacking
      but clearly required.

      Methods/design: TJDBPS07 is a multicenter prospective, randomized controlled, trial comparing
      TLPD and OPD in pancreatic cancers. A total of 200 patients with pancreatic cancer underwent
      PD will be randomly allocated to the TLPD group or OPD group with an enhanced recovery after
      surgery (ERAS) pattern. The trial's aim is to exploring the overall survival (OS), disease
      free survival (DFS) and quality of life. The duration of the entire trial is seven years
      including prearrangement, a presumably five-year follow-up and analyses.

      Discussion: Despite the fact there are several RCTs comparing minimally invasive
      pancreaticoduodenectomy (MIPD) and Open approach or LPD versus OPD. This trial will be the
      first comparing TLPD and OPD in a large multicenter setting. TJDBPS01 trial is hypothesized
      to assess whether TLPD has superiority over OPD in recovery and other aspects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>5-year overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 year</time_frame>
    <description>Disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 year</time_frame>
    <description>3-year overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Laparoscopic</condition>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>TLPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total laparoscopic pancreaticoduodenectomy for pancreatic cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open pancreaticoduodenectomy for pancreatic cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TLPD Surgery</intervention_name>
    <description>TLPD</description>
    <arm_group_label>TLPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>OPD Surgery</intervention_name>
    <description>OPD</description>
    <arm_group_label>OPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven pancreatic cancer.

          2. Highly presumed malignancy with difficulties to obtain histological evidence.

          3. Preoperative staging work up performed by upper abdomen enhanced CT scan.

          4. The subject understands the nature of this trial and willing to comply.

          5. Ability to provide written informed consent.

          6. Patients treated with curative intent in accordance to international guidelines

        Exclusion Criteria:

          1. Distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node
             metastases, involvement of other organs.

          2. Subjects undergoing left, central or total pancreatectomy or any surgical procedures
             except pancreaticoduodenectomy.

          3. Patients with high operative risk as defined by the American Society of
             Anesthesiologists (ASA) score &gt;4.

          4. Synchronous malignancy in other organs.

          5. Previous underwent pancreatic resections.

          6. Palliative surgery.

          7. Pregnancies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renyi Qin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renyi Qin</last_name>
    <phone>+8602783665314</phone>
    <email>172356995@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hag Zhang</last_name>
    <phone>+8602783665314</phone>
    <email>172356995@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Biliary and Pancreatic Surgery, Tongji Hospital, Affiliated Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Renyi Qin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Carcinoma</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Pancreaticoduodenectomy</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

